In addition, while CAPS and FMF patients are treated effectively with IL-1-antagonizing therapeutics (33), an NLRC4V341A-expressing AIFEC patient was found to be refractory to anakinra treatment. The gene discussed is IL1B; the disease is periodic fever-infantile enterocolitis-autoinflammatory syndrome.